🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting in excess of 82 million infections annually. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to data published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This places it at an comparable level with the current standard treatment, which involves an injection and a pill. The research included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have expressed hope. Access to a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is considered vital to reduce the burden of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.